PeptiDream Announces Strategic Partnership with Drug-Delivery Expert PharmaIN

Download PDF

Press Release

PeptiDream Announces Strategic Partnership with Drug-Delivery Expert PharmaIN

 

Bothell, WA & Kanagawa, Japan – (June 5th, 2019) – PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today a strategic partnership with Seattle-based PharmaIN Corporation (“PharmaIN”) for the purpose of investigating the use of PharmaIN’s proprietary drug carrier and delivery Protected Graft Co-Polymer (“PGC™”) technology in combination with PeptiDream’s peptide discovery and development programs.

PharmaIN’s breakthrough PGC™ technology is a PEG-based excipient that reversibly binds the therapeutic peptide and unlike PEGylation or other peptide PK extending technologies, does not require the peptide to be modified in anyway, thereby fully preserving the potency, function, and mobility of the therapeutic peptide payload. Additionally, the PGC™ technology offers a number of other potentially significant advantages in that it can improve the solubility of the peptide payload, protects the peptide payload from degradation, thereby increasing stability, and acts to slowly releases the peptide payload resulting in a significantly longer circulation half-life. The PGC™ technology has also shown to passively target the peptide payload to tumor sites/ sites of inflammation/infection and can significantly decrease the risk of injection site reactions common to conventional injectables.

Under the partnership, PeptiDream will have the ability to broadly use PharmaIN’s PGC™ technology across its discovery programs to formulate applicable therapeutic peptides with PGC™ and evaluate in vivo the drug carrier/delivery benefits. Clinical development and commercialization of any peptide employing PharmaIN’s PGC™ technology would require a specific development and commercialization license.

[Comment from Patrick Reid, CEO of PeptiDream Inc.]

“PharmaIN has developed a very unique and attractive drug carrier/delivery technology that doesn’t require modification of the therapeutic peptide payload and could add significant formulation, administration, and delivery benefits to both our internal and external therapeutic
programs in which the intended administration route is an injectable. We greatly look forward to working with PharmaIN and being able to evaluate the PGC™ technology in such programs.”

[Comment from Elijah Bolotin, CEO of PharmaIN Corp.]

“We are very excited to be working with PeptiDream, one of the world’s leaders in the discovery and development of peptide therapeutics. We believe our PGC™ technology offers significant advantages/benefits over conventional carrier/delivery technologies, especially for injectable peptide therapeutics. This partnership will allow us to showcase our PGC™ technology across PeptiDream’s applicable development programs and extensive list of pharmaceutical partners.”

About PeptiDream Inc.:

PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit www.peptidream.com.

About PharmaIN:

PharmaIN Corporation, headquartered in Bothell, WA, (near Seattle) is developing superior drug therapies by using its “Protected Graft Co-polymer” (PGC™) excipient and innovative peptide engineering technologies to enable effective and safe injectable peptide therapeutics. Besides peptides, PGC™ excipient can be beneficial to improve PK, bioavailability, stability and solubility of numerous proteins and some poorly soluble potent small molecules. PharmaIN works with partner companies to enable new, value-added drug therapies and improve “old” drugs using these platforms.

Enquiries:

PeptiDream Inc.
Patrick C Reid +81-44-270-1270 (Kanagawa)

PharmaIN Corp.
Mark Edelsward +1-206-568-1450 (Seattle)

PharmaIN Corporation Announces Attendance at the 2019 J.P. Morgan Healthcare Conference.

Press Release

PharmaIN Corporation Announces Attendance at the 2019 J.P. Morgan Healthcare Conference. 

 

Bothell, WA, USA – 4 December 2018  PharmaIN Corporation announced its attendance at the J.P. Morgan Healthcare Conference, the largest and most informative healthcare investment symposium in the industry. This three-day event will be held on January 7-10, 2019 at the Westin St. Francis Hotel in San Francisco, California.  

Elijah Bolotin, CEO and founder, and Mark Edelsward, Director of Business Development, will be meeting with current and prospective collaborators during the conference.  

Please contact Mark Edelsward if PharmaIN’s half-life extension technologies are of interest and you would like to arrange a meeting. 

About the Conference 

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community. 

 About PharmaIN 

PharmaIN Corporation, headquartered in Bothell, WA, (near Seattle) is developing superior drug therapies by using its “Protected Graft Co-polymer” (PGC™) excipient and innovative peptide engineering technologies to enable effective and safe injectable peptide therapeutics. Besides peptides, PGC excipient can be beneficial to improve PK, bioavailability, stability and solubility of numerous proteins and some poorly soluble potent small molecules. PharmaIN works with partner companies to enable new, value-added drug therapies and improve “old” drugs using these platforms. Visit www.PharmaIN.com.

PharmaIN Corporation and Polypeptide Therapeutic Solutions (PTS) Announce Collaboration Agreement for Contract Manufacturing

Press Release

PharmaIN Corporation and Polypeptide Therapeutic Solutions (PTS) Announce Collaboration Agreement for Contract Manufacturing

 

Bothell, WA & Valencia, Spain – 21st September 2018  PharmaIN Corporation and Polypeptide Therapeutic Solutions (PTS) announced today that they have entered into a collaboration agreement for contract manufacturing.

Under the agreement, Polypeptide Therapeutic Solutions will provide PharmaIN contract research services and own technology to add as a part of PharmaIN´s Protected Graft Co-Polymer (PGCTM) delivery Platform. Within the agreement, PTS will also support PGC® program in terms of GMP grade and large-scale manufacturing of key starting materials for PGC® within PTS´s brand new GMP facilities.

”PTS has been a great partner and we were excited to hear that they were building GMP grade production facilities” commented Dr Elijah Bolotin , CEO of PharmaIN.

”Our pipeline products will require GMP grade components as they enter clinical trials and knowing we can depend on a reliable and responsive partner like PTS gives us confidence on those. PTS has provided PharmaIN with the high-quality polymers of unmatched polydispersity and top-notch analytical support.” commented Dr Sergey Rakhilin, Director of Product Development, PharmaIN.

“We teamed with PharmaIN and were able to deliver a consistent and robust material in less than nine months, helping our partner to reduce time, costs and risks.” says Jose Vicente Pons, Chief Executive Officer at PTS.

“We are very delighted to see the results of the collaboration and to strengthen our relationship with PharmaIN with this agreement” commented Vicent J. Nebot, Chief Technical Officer at PTS.

About PharmaIN
PharmaIN Corporation, headquartered in Bothell, WA, (near Seattle) is developing superior drug therapies by using its “Protected Graft Co-polymer” (PGC™) excipient and innovative peptide engineering technologies to enable effective and safe injectable peptide therapeutics. Besides peptides, PGC excipient can be beneficial to improve PK, bioavailability, stability and solubility of numerous proteins and some poorly soluble potent small molecules. PharmaIN works with partner companies to enable new, value-added drug therapies and improve “old” drugs using these platforms. Visit www.PharmaIN.com.

About Polypeptide Therapeutic Solutions
PTS is a company devoted to the design and manufacture of polypeptide-based materials for drug delivery and high-tech applications. Proprietary know-how & IP to provide a 360º solution from early research, through scale-up to first preclinical batches, analytical solutions within a GLP certified QC laboratory and brand new GMP facility for manufacturing clinical grade polypeptide-based therapeutics. Please visit www.pts-polypeptides.com.

PharmaIN and Shionogi Announce Collaboration and $17M Securities Purchase Agreements

Download PDF

Press Release

PharmaIN and Shionogi Announce Collaboration and $17M Securities Purchase Agreements

 

Bothell, WA & Osaka, Japan – (January 4th, 2018) – PharmaIN Corporation and Shionogi & Co., LTD announced today that they entered into a Collaboration Agreement with an exclusive two-year Option to negotiate a License for the collaboration product.

Shionogi Corp. will make an equity investment of up to $17M USD in PharmaIN in three tranches.

“We’ve enjoyed working with Shionogi since initial proof of concepts and are excited to expand our collaboration to advance novel, first in class therapy to benefit many millions of patients.  As a major research-driven pharmaceutical company Shionogi brings valuable experience, resources and innovation to our partnership,” said Elijah Bolotin, PhD, President and CEO of PharmaIN Corp.

” Shionogi is very pleased to start this collaboration with PharmaIN, which has innovative platform technologies for drug discovery of various molecules including peptides, proteins and small molecules. We look forward to this collaboration that will surely bring us the great opportunity to provide many patients with innovative medicines,” said Takeshi Shiota, PhD, Corporate Officer, Senior Vice President, Pharmaceutical Research Division.

About PharmaIN: PharmaIN Corporation, headquartered in Bothell, WA, (near Seattle) is developing superior drug therapies by using its “Protected Graft Co-polymer” (PGC™) excipient and innovative peptide engineering technologies to enable effective and safe injectable peptide therapeutics. Besides peptides, PGC excipient can be beneficial to improve PK, bioavailability, stability and solubility of numerous proteins and some poorly soluble potent small molecules. PharmaIN works with partner companies to enable new, value-added drug therapies and improve “old” drugs using these platforms.  Visit www.pharmain.com.

About Shionogi & Co., Ltd.:

Shionogi &Co., Ltd. is a major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” Shionogi’s research and development currently targets two therapeutic areas: infectious diseases, and pain/CNS disorders. For over 50 years, Shionogi has developed and commercialized innovative oral and parenteral anti-infectives. In addition, Shionogi is engaged in new research areas, such as obesity/geriatric metabolic diseases and oncology/immunology. Contributing to the health and QOL of patients around the world through development in these therapeutic areas is Shionogi’s primary goal. For more details, please visit www.shionogi.co.jp/en/.